Skip to Content

Omalizumab Side Effects

In Summary

More frequently reported side effects include: lower leg pain. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to omalizumab: subcutaneous powder for solution


Subcutaneous route (Powder for Solution)

Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported with omalizumab administration. Anaphylaxis may occur at any time from the first dose to more than a year after omalizumab initiation. Closely monitor patients after omalizumab administration and prepare to manage any anaphylactic reactions.

Along with its needed effects, omalizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking omalizumab:

Less Common

  • Blistering, crusting, irritation, itching, or reddening of the skin
  • body produces substance that can bind to drug making it less effective or cause side effects


Incidence Not Known

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • chest pain
  • chills
  • difficulty in moving
  • fever
  • muscle pain or stiffness
  • pain in the joints
  • painful or difficult urination
  • pinpoint red spots on the skin
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen glands
  • unusual bleeding or bruising

Some side effects of omalizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • body aches or pain
  • cold or flu-like symptoms
  • congestion
  • dryness or soreness of the throat
  • headache
  • hoarseness
  • leg pain
  • lumps
  • pain or tenderness around the eyes and cheekbones
  • stuffy or runny nose
  • voice changes

Less Common

  • Arm pain
  • cracked, dry, or scaly skin
  • earache

Incidence Not Known

For Healthcare Professionals

Applies to omalizumab: subcutaneous powder for injection, subcutaneous solution


The more commonly reported side effects included injection site reactions, headache, and nasopharyngitis.[Ref]


In clinical trials, any injection site reaction occurred in 45% and 43% of patients given this drug and placebo, respectively; severe reactions occurred in 12% and 9%, respectively.[Ref]

Very common (10% or more): Any injection site reaction, including pain, swelling, itching, redness, bruising, bleeding, induration, or mass (up to 45%), severe injection site reaction (up to 12%)

Uncommon (0.1% to 1%): Arm swelling[Ref]


Very common (10% or more): Viral infection (up to 37%)

Uncommon (0.1% to 1%): Moniliasis, parasitic infection

Rare (0.01% to 0.1%): Anti-omalizumab antibody development

Postmarketing reports: Serum sickness, allergic granulomatous angiitis (Churg-Strauss syndrome), lymphadenopathy[Ref]

In clinical studies, viral infection occurred in 37% and 39% or patients given this drug or placebo, respectively. Increased parasitic infections, compared to placebo, were not statistically significant.[Ref]

Nervous system

Very common (10% or more): Headache (up to 27%)

Common (1% to 10%): Dizziness

Uncommon (0.1% to 1%): Syncope, vasovagal syncope, somnolence, paresthesia

Frequency not reported: Migraine, sinus headache[Ref]

In clinical trials, headache occurred in 37% of patients given either this drug (n=716) or placebo (n=694); headache occurred very commonly in patients 6 to 12 years old.[Ref]


Very common (10% or more): Back pain (up to 13%)

Common (1% to 10%): Arthralgia, myalgia, sprains, strains, extremity pain, fracture

Postmarketing reports: Joint swelling[Ref]


In clinical trials with chronic idiopathic urticarial, patients reported nasopharyngitis 9.1%, 6.6%, and 7% in 150 mg, 300 mg, and placebo, respectively; sinusitis (1.1%, 4.9%, 2.1%), cough (1.1%, 2.2%,1.2%), and upper respiratory infection (11.1%, 3.4%, 2.1%) were also reported by patients, respectively.[Ref]

Common (1% to 10%): Nasopharyngitis, sinusitis, viral upper respiratory infection (URI), URI

Uncommon (0.1% to 1%): Pharyngitis, cough, allergic bronchospasm

Rare (0.01% to 0.1%): Laryngoedema

Frequency not reported: Asthma, oropharyngeal pain[Ref]


Common (1% to 10%): Dermatitis, pruritus

Uncommon (0.1% to 1%): Skin rashes, flushing, photosensitivity

Postmarketing reports: Alopecia, hair loss[Ref]


Common (1% to 10%): Fever, earache

Uncommon (0.1% to 1%): Fatigue, post-injection phenomena[Ref]

In clinical trials, fever occurred very commonly in patients 6 to 12 years old.[Ref]


In clinical trials, upper abdominal pain was very common in patients 6 to 12 years old. In clinical trials with chronic idiopathic urticarial, patients reported nausea 1.1%, 2.7%, and 2.5% of the time with 150 mg, 300 mg, and placebo, respectively.[Ref]

Common (1% to 10%): Upper abdominal pain, nausea

Uncommon (0.1% to 1%): Diarrhea, dyspepsia, gastroenteritis

Frequency not reported: Toothache[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Uncommon (0.1% to 1%): Urticaria

Rare (0.01% to 0.1%): Anaphylactic reactions, angioedema

Postmarketing reports: Anaphylactoid reactions[Ref]


Uncommon (0.1% to 1%): Postural hypotension

Frequency not reported: Peripheral edema, arterial thrombotic events (including transient ischemic attack, myocardial infarction, unstable angina, and cardiovascular death)

Postmarketing reports: Hypotension, chest tightness[Ref]


Uncommon (0.1% to 1%): Asymptomatic platelet decreases

Postmarketing reports: Idiopathic severe thrombocytopenia, eosinophilic conditions[Ref]

In clinical trials, 0.6% of patients developed decreased platelet counts below the normal laboratory range; these patients did not have associated bleeding episodes or decreased hemoglobin.[Ref]


Uncommon (0.1% to 1%): Weight increases[Ref]


Frequency not reported: Anxiety[Ref]


1. "Product Information. Xolair (omalizumab)." Genentech, South San Francisco, CA.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.